Zaghloul Hadeel, Malik Rayaz A
Department of Medicine, Weill Cornell Medicine, Doha, Qatar.
Department of Medicine, Weill Cornell Medicine - Qatar, Qatar Foundation, Education City, P.O. Box 24144, Doha, Qatar.
Ther Adv Endocrinol Metab. 2022 Jul 11;13:20420188221110708. doi: 10.1177/20420188221110708. eCollection 2022.
The coronavirus disease 2019 (COVID-19) pandemic affected at least 200 million individuals worldwide and resulted in nearly 5 million deaths as of October 2021. According to the latest data from the International Diabetes Federation (IDF) in 2021, the diabetes pandemic has affected 537 million people and is associated with 6.7 million deaths. Given the high prevalence of both diabetes and COVID-19 and common pathological outcomes, a bidirectional relationship could have a catastrophic outcome. The increased risk of COVID-19 in those with obesity and diabetes and higher morbidity and mortality has received considerable attention. However, little attention has been given to the relationship between COVID-19 and microvascular complications. Indeed, microvascular complications are associated with an increased risk of cardiovascular disease (CVD) and mortality in diabetes. This review assesses the evidence for an association between diabetic microvascular complications (neuropathy, nephropathy, and retinopathy) and COVID-19. It draws parallels between the pathological changes occurring in the microvasculature in both diseases and assesses whether microvascular disease is a prognostic factor for COVID-19 outcomes in diabetes.
2019年冠状病毒病（COVID-19）大流行截至2021年10月已影响全球至少2亿人，并导致近500万人死亡。根据国际糖尿病联合会（IDF）2021年的最新数据，糖尿病大流行已影响5.37亿人，并导致670万人死亡。鉴于糖尿病和COVID-19的高患病率以及共同的病理结局，双向关系可能会产生灾难性后果。肥胖和糖尿病患者感染COVID-19的风险增加以及更高的发病率和死亡率已受到相当多的关注。然而，COVID-19与微血管并发症之间的关系却很少受到关注。事实上，微血管并发症与糖尿病患者心血管疾病（CVD）风险增加和死亡率相关。本综述评估了糖尿病微血管并发症（神经病变、肾病和视网膜病变）与COVID-19之间关联的证据。它比较了两种疾病微血管中发生的病理变化，并评估微血管疾病是否是糖尿病患者COVID-19结局的预后因素。
